Ipsen Management

Management criteria checks 4/4

Ipsen's CEO is David Loew, appointed in Jul 2020, has a tenure of 3.83 years. total yearly compensation is €4.36M, comprised of 22.6% salary and 77.4% bonuses, including company stock and options. directly owns 0.061% of the company’s shares, worth €5.77M. The average tenure of the management team and the board of directors is 5 years and 10.5 years respectively.

Key information

David Loew

Chief executive officer

€4.4m

Total compensation

CEO salary percentage	22.6%
CEO tenure	3.8yrs
CEO ownership	0.06%
Management average tenure	5yrs
Board average tenure	10.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Loew's remuneration changed compared to Ipsen's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Compensation vs Market: David's total compensation ($USD4.65M) is about average for companies of similar size in the French market ($USD4.75M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Loew (56 yo)

3.8yrs

Tenure

€4,361,753

Compensation

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Loew	MD, CEO & Director	3.8yrs	€4.36m	0.061% € 5.8m
Aymeric Le Chatelier	Executive VP & CFO	9.5yrs	€1.02m	no data
Aidan Murphy	Executive VP and Head of Technical Operations	6.3yrs	no data	no data
Craig Marks	Vice-President of Investor Relations	no data	no data	no data
Francois Garnier	Executive VP of Legal Affairs	9.4yrs	no data	no data
Gwenan White	Executive VP and Head of Communications	3.2yrs	no data	no data
Regis Mulot	Executive VP & Chief Human Resources Officer	6.2yrs	no data	no data
Dominique Bery	Head of Nordics & Baltics	7.1yrs	no data	no data
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	3.7yrs	no data	no data
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	3.6yrs	no data	no data
James Levine	President of Fondation Ipsen	no data	no data	no data
Mari Scheiffele	Executive VP & President of International	2.5yrs	no data	no data

5.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: IPN's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Loew	MD, CEO & Director	4yrs	€4.36m	0.061% € 5.8m
Marc M. de Garidel	Non-Executive Chairman	13.5yrs	€600.00k	0.17% € 15.8m
Margaret Liu	Independent Director	6.9yrs	€130.00k	0.00083% € 78.2k
Michèle Ollier	Director	9yrs	€65.00k	0.00061% € 57.5k
Karen Witts	Independent Director	2.3yrs	€115.00k	0.00061% € 57.5k
Antoine Flochel	Vice Chairman	18.8yrs	€165.00k	0.0036% € 342.1k
Henri Beaufour	Director	18.8yrs	€36.00k	0% € 0
Anne Beaufour	Director	18.8yrs	€45.00k	26.41% € 2.5b
Carol Xueref	Director	11.9yrs	€115.00k	0.00061% € 57.5k
Philippe Bonhomme	Director	12.3yrs	€95.00k	0% € 0
Piet Wigerinck	Independent Director	6yrs	€78.00k	0.00082% € 77.3k
Laetitia Ducroquet	Employees Representative Director	3.5yrs	no data	0.0010% € 94.2k

10.5yrs

Average Tenure

59.5yo

Average Age

Experienced Board: IPN's board of directors are seasoned and experienced ( 10.5 years average tenure).

Ipsen Management

Management criteria checks 4/4

Key information

Recent management updates

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Recent updates

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Dividend of €1.20 announced

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 31%?

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 34% Undervaluation?

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen (EPA:IPN) Is Due To Pay A Dividend Of €1.20

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Upcoming dividend of €1.20 per share

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Is Ipsen (EPA:IPN) A Risky Investment?

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Full year 2021 earnings: EPS exceeds analyst expectations

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Investor sentiment deteriorated over the past week

Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet